PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies.

Abstract Mucositis of the oral cavity and pharynx is a major dose-limiting factor in the application of radiotherapy (RT) to patients with head and neck cancer. Therefore, we evaluated the wound healing effect of human recombinant epidermal growth factor (rhEGF) in head and neck cancer and lymphoma patients with irradiation (with or without combined chemotherapy-induced oral mucositis). Patients at Asan Medical Center who had undergone definitive RT of the head and neck region with or without combined chemotherapy and who had developed severe oral mucositis (higher than the Radiation Therapy Oncology Group grade 3) were treated with topical rhEGF twice daily for 7 days. The evaluation of response with regard to oral mucositis was performed 1 week later. Of the 11 treated patients, three had nasopharyngeal carcinoma, three had carcinoma of the oropharynx, two had carcinoma of the oral cavity, one had carcinoma of the hypopharynx and two had lymphoma of the head and neck. Six patients received RT only, and five patients received concurrent chemoradiotherapy. All patients showed improvements in their oral mucositis after topical treatment with rhEGF in that the Radiation Therapy Oncology Group grade was significantly decreased (P = 0.0000). This finding suggests that rhEGF is effective and safe for the treatment of radiation-induced mucositis. Further studies are needed to determine the optimal dosage and fractionation schedule.
PMID
Related Publications

Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes.

Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.

Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis.

Therapeutic effects of recombinant human epidermal growth factor (rhEGF) in a murine model of concurrent chemo- and radiotherapy-induced oral mucositis.

Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.

Authors

Mayor MeshTerms
Keywords
Journal Title european journal of cancer care
Publication Year Start




PMID- 19456848
OWN - NLM
STAT- MEDLINE
DCOM- 20100428
LR  - 20170220
IS  - 1365-2354 (Electronic)
IS  - 0961-5423 (Linking)
VI  - 18
IP  - 6
DP  - 2009 Nov
TI  - Recombinant human epidermal growth factor treatment of radiation-induced severe
      oral mucositis in patients with head and neck malignancies.
PG  - 636-41
LID - 10.1111/j.1365-2354.2008.00971.x [doi]
AB  - Mucositis of the oral cavity and pharynx is a major dose-limiting factor in the
      application of radiotherapy (RT) to patients with head and neck cancer.
      Therefore, we evaluated the wound healing effect of human recombinant epidermal
      growth factor (rhEGF) in head and neck cancer and lymphoma patients with
      irradiation (with or without combined chemotherapy-induced oral mucositis).
      Patients at Asan Medical Center who had undergone definitive RT of the head and
      neck region with or without combined chemotherapy and who had developed severe
      oral mucositis (higher than the Radiation Therapy Oncology Group grade 3) were
      treated with topical rhEGF twice daily for 7 days. The evaluation of response
      with regard to oral mucositis was performed 1 week later. Of the 11 treated
      patients, three had nasopharyngeal carcinoma, three had carcinoma of the
      oropharynx, two had carcinoma of the oral cavity, one had carcinoma of the
      hypopharynx and two had lymphoma of the head and neck. Six patients received RT
      only, and five patients received concurrent chemoradiotherapy. All patients
      showed improvements in their oral mucositis after topical treatment with rhEGF in
      that the Radiation Therapy Oncology Group grade was significantly decreased (P = 
      0.0000). This finding suggests that rhEGF is effective and safe for the treatment
      of radiation-induced mucositis. Further studies are needed to determine the
      optimal dosage and fractionation schedule.
FAU - Hong, J P
AU  - Hong JP
AD  - Department of Plastic and Reconstructive Surgery, University of Ulsan College of 
      Medicine, Asan Medical Center, Seoul, Korea.
FAU - Lee, S-W
AU  - Lee SW
FAU - Song, S Y
AU  - Song SY
FAU - Ahn, S D
AU  - Ahn SD
FAU - Shin, S S
AU  - Shin SS
FAU - Choi, E K
AU  - Choi EK
FAU - Kim, J H
AU  - Kim JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090423
PL  - England
TA  - Eur J Cancer Care (Engl)
JT  - European journal of cancer care
JID - 9301979
RN  - 0 (Radiation-Protective Agents)
RN  - 0 (Recombinant Proteins)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - N
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Epidermal Growth Factor/*administration & dosage
MH  - Female
MH  - Head and Neck Neoplasms/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mouth Mucosa/*radiation effects
MH  - Pilot Projects
MH  - Radiation Injuries/*drug therapy/etiology
MH  - Radiation-Protective Agents/*administration & dosage
MH  - Radiotherapy/adverse effects
MH  - Recombinant Proteins/therapeutic use
MH  - Stomatitis/*drug therapy/etiology
MH  - Treatment Outcome
MH  - Wound Healing/drug effects
PMC - PMC2776929
OID - NLM: PMC2776929
EDAT- 2009/05/22 09:00
MHDA- 2010/04/29 06:00
CRDT- 2009/05/22 09:00
PHST- 2009/05/22 09:00 [entrez]
PHST- 2009/05/22 09:00 [pubmed]
PHST- 2010/04/29 06:00 [medline]
AID - ECC971 [pii]
AID - 10.1111/j.1365-2354.2008.00971.x [doi]
PST - ppublish
SO  - Eur J Cancer Care (Engl). 2009 Nov;18(6):636-41. doi:
      10.1111/j.1365-2354.2008.00971.x. Epub 2009 Apr 23.